Newsfile Corp
06 Jul 2026, 12:42 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA issued a second Complete Response Letter (CRL) for Unicycive Therapeutics' OLC New Drug Application, citing recurring third-party manufacturing deficiencies. — A second CRL indicates a failure to resolve previous regulatory hurdles, significantly delaying or blocking the path to commercialization for a key product.
-0.90The FDA had not yet inspected the third-party manufacturing vendor prior to issuing the second CRL for the resubmitted application. — This suggests a breakdown in the submission process or a failure in the company's quality oversight of its supply chain.
-0.60Law firm Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations and misleading statements regarding the FDA review process. — The threat of a securities class action lawsuit adds legal risk and potential financial liabilities to the company's existing regulatory setbacks.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is the subject of a securities fraud class action lawsuit alert regarding significant investor losses.
The company is under investigation for potential securities law violations following a second FDA Complete Response Letter and a declining stock price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
